SAMBA, in my opinion, is simply a reflection of Dwight's industry connections. Major money can be generated from the cord blood bank that Histostem has developed. The larger the network of hospitals and healthcare organizations that are affiliated with AMST that conduct R&D using stem cells derived from cord blood increases the likelihood of large cash flows as organizations pay for the stem cells they need. This is a monster connection that Dwight has brought to Histostem -- a network of potential users for the stem cells in the blood bank. We shall see how this all plays out. Hopefully we hear something in the near term.
Market Data 
Markets 
AI
